Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435515 | 0.90 | POLB (0.41) | POLBRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL237958 | 0.88 | POLB (0.54) | POLBRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL342420 | 0.88 | POLB (0.45) | POLBRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL5133715 | 0.86 | LMNA (0.36) | POLBRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL12092095 | 0.84 | LMNA (0.42) | POLBRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL7200996 | 0.83 | POLB (0.34) | POLBRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL42368 | 0.82 | ALDH1A1 (0.44) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL29352062 | 0.82 | ALDH1A1 (0.44) | RAB9ANPC1MAPTSMN1; SMN2HPGD | |
| SCHEMBL2050169 | 0.81 | POLB (0.35) | POLBRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL29356575 | 0.81 | ALDH1A1 (0.39) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240011011-A1 | BIOCATALYTICAL COMPOSITION | INOFEA GMBH (CH) | 2024-01-11 | — | — | US | claimed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| US-10155046-B2 | Activated sialic acid derivatives for protein derivatisation and conjugation | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2018-12-18 | — | — | US | claimed |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2018-09-20 | — | — | US | claimed |
| EP-2494075-B1 | TEMPLATED NANOCONJUGATES | UNIV NORTHWESTERN (US) | 2018-04-04 | — | — | EP | claimed |
| EP-1853634-B1 | ACTIVATED SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION | LIPOXEN TECHNOLOGIES LTD (GB) | 2016-08-10 | — | — | EP | claimed |
| EP-1776389-B1 | SIALIC ACID DERIVATIVES | LIPOXEN TECHNOLOGIES LTD (GB) | 2016-06-29 | — | — | EP | claimed |
| US-20160168559-A1 | BIOCATALYTICAL COMPOSITION | INOFEA GMBH (CH) | 2016-06-16 | — | — | US | claimed |
| US-20160120993-A1 | Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2016-05-05 | — | — | US | claimed |
| US-9216227-B2 | Activated sialic acid derivatives for protein derivatisation and conjugation | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2015-12-22 | — | — | US | claimed |
| WO-2007122259-A1 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS. APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-11-01 | — | — | WO | claimed |
| EP-1776389-A2 | SIALIC ACID DERIVATIVES | Lipoxen Technologies Limited (GB) | 2007-04-25 | — | — | EP | claimed |
| EP-0942996-B1 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | DIATIDE INC (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2006090119-A1 | ACTIVATED SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2006-08-31 | — | — | WO | claimed |
| WO-2006016168-A2 | SIALIC ACID DERIVATIVES | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2006-02-16 | — | — | WO | claimed |
| US-6335176-B1 | REAGENT IS SUCCINIMIDYL MOIETY LINKED TO KINASE SUBSTRATE; CAN BE LINKED TO FREE PRIMARY OR SECONDARY AMINE IN COMPOUND TO BE PHOSPHORYLATED | PHARMACOPEIA, INC. | 2002-01-01 | — | — | US | claimed |
| US-5951981-A | A CROSSLINKED THROMBOLYTIC PROTEINASE, E.G. FIBROLASE FROM AGKISTRODOON CONTORTRIX CONFORTRIX VENOM, AND A BINDING PEPTIDE THAT BINDS AT THE SITE OF BLOOD CLOTS AND THROMBI; SIDE EFFECTS REDUCTION | DIATIDE, INC. (US) | 1999-09-14 | — | — | US | claimed |
| EP-0701448-A4 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 1997-01-02 | — | — | EP | claimed |
| EP-0701448-A1 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-20 | — | — | EP | claimed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | POLB 3635/4885RAB9A 4326/4885NPC1 4476/4885 |
| US-10155046-B2 | Activated sialic acid derivatives for protein derivatisation and conjugation | NANS, SPAST, NEU1 | POLB 4700/4885RAB9A 2234/4885NPC1 3868/4885 |
| US-20160120993-A1 | Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation | NANS, SPAST, NEU1 | POLB 4700/4885RAB9A 2234/4885NPC1 3868/4885 |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | POLB 4746/4885RAB9A 4490/4885NPC1 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.